Stage 4 diffuse pleural mesothelioma is defined by the presence of distant metastatic disease (M1). According to the AJCC/UICC TNM Version 9 staging system, pleural mesothelioma is classified as Stage IV when distant metastasis is present, regardless of the primary tumor or regional lymph-node category:

Any T, Any N, M1

This distinction is important. Stage 4 is not defined solely by a large pleural tumor, extensive chest-wall invasion, or regional lymph-node involvement. A T4 tumor remains Stage IIIB if distant metastasis is absent and the disease is M0.

Stage 4 is advanced disease and is generally not curable with current standard therapies. However, treatment continues. Systemic therapy, symptom management procedures, selected radiation therapy, clinical trials, and palliative care remain important. ASCO recommends systemic treatment for eligible patients, as it can improve survival and quality of life.

Stage 4 Mesothelioma at a Glance

What Does Stage 4 Mesothelioma Mean?

Pleural mesothelioma staging uses three components:

• T — Tumor: the extent of the primary pleural tumor.
• N — Nodes: whether regional lymph nodes contain mesothelioma.
• M — Metastasis: whether the cancer has spread to distant sites.

In Stage IV, the defining component is M1.

A patient can therefore have different T and N categories and still have Stage IV disease as long as distant metastatic disease has been identified.

The official Version 9 stage grouping is:

Stage IV = Any T + Any N + M1

This means the primary tumor does not have to be T4, and extensive regional nodal disease is not required.

AJCC Version 9: Any T, Any N, M1

Version 9 more clearly distinguishes advanced locoregional disease from distant metastatic disease than many simplified online explanations.

For example:

Stage IIIB
T4, Any N, M0

versus:

Stage IV
Any T, Any N, M1

A T4 tumor may invade major structures such as mediastinal organs, ribs, diaphragm, or pericardium, and may extend to the contralateral pleura. Without distant metastasis, it remains M0 and is classified as Stage IIIB.

Stage IV requires distant metastasis.

Therefore, statements like “Stage 4 means the tumor has grown very far in the chest” are incomplete. Local tumor extent and distant metastasis are separate components of TNM staging.

What Does M1 Mean?

M1 means distant metastatic disease has been identified.

Metastatic disease occurs when mesothelioma cells spread to sites distant from the primary pleural tumor.

Examples of distant involvement described in current patient-facing staging resources include sites such as:

• bone;
• liver;
• peritoneum;
• distant lymph nodes;
• the opposite lung or pleural region when involvement represents distant metastatic spread rather than direct contiguous extension;
• other distant organs or tissues.

An Important Contralateral Pleura Distinction

This distinction requires careful attention.

Under TNM Version 9, direct extension of the primary tumor to the contralateral pleura is a T4 feature. If there is no distant metastasis, T4 Any N M0 is Stage IIIB.

By contrast, separate metastatic involvement of the opposite lung or pleural region can represent distant disease and therefore M1. Current ACS staging information lists distant spread to the opposite lung or pleura among examples of Stage IV disease.

Imaging findings on the opposite side of the chest require clinical interpretation and should not be automatically labeled as Stage IV. ASCO notes that further evaluation may be appropriate when contralateral pleural abnormalities are found and the distinction could affect treatment planning.

Where Can Stage 4 Mesothelioma Spread?

Distant metastatic pleural mesothelioma can involve several sites. Current authoritative patient resources describe metastatic disease involving areas such as the peritoneum, bones, liver, the opposite lung or pleural region, distant lymph nodes, and other organs.

Metastatic patterns vary among patients.

Some patients have limited distant metastases, while others have more widespread disease. The Stage IV label alone does not reflect total disease burden.

Metastasis location also influences symptoms and treatment decisions.

Stage 3 vs Stage 4 Mesothelioma

The most important difference is M status.

Version 9 places T4 Any N M0 in Stage IIIB, while any T/any N with M1 is Stage IV.

A patient can therefore have very extensive local Stage IIIB disease without distant metastasis. In contrast, another patient with a less extensive primary tumor can be Stage IV because an M1 metastasis has been identified. See our Stage 3 mesothelioma guide for more detail.

Symptoms of Stage 4 Mesothelioma

No specific symptom pattern can diagnose Stage 4 mesothelioma or reliably distinguish it from other stages.

Possible symptoms of pleural mesothelioma include:

• shortness of breath;
• chest or rib-area pain;
• cough;
• fatigue;
• reduced exercise tolerance;
• pleural fluid accumulation;
• reduced appetite;
• unintended weight loss.

In Stage IV disease, additional symptoms may occur depending on where metastatic disease is located, but symptoms alone cannot establish M1 status.

A patient with extensive pleural fluid can be very breathless even without widespread metastatic disease, while another patient with Stage IV disease may initially have comparatively modest symptoms.

Stage is determined by clinical evaluation, pathology, and imaging, not by symptom severity. Our symptoms guide covers the broader range of possible signs across all stages.

How Is Stage 4 Mesothelioma Diagnosed?

Diagnosis and staging involve two different questions:

1. Is the disease pleural mesothelioma?
2. How far has it spread?

When antineoplastic treatment is planned, ASCO strongly recommends adequate tissue sampling, typically through thoracoscopic biopsy when feasible, because histologic subtype can materially affect treatment selection. Our diagnosis guide and tests and biopsy guide cover this process in more detail.

Pleural Fluid Evaluation

If symptomatic pleural effusion is present, ASCO recommends initial thoracentesis with cytologic examination as part of the assessment.

Thoracentesis can serve two purposes:

• obtain pleural fluid for evaluation;
• relieve breathlessness caused by fluid accumulation.

However, treatment planning often requires sufficient tissue to confirm histology and conduct further pathological studies.

Biopsy and Histology

A biopsy can establish the diagnosis and determine histologic subtype.

The major categories include:

• epithelioid;
• biphasic;
• sarcomatoid.

Histology is important because treatment outcomes and preferred systemic approaches differ among these groups.

Contrast-Enhanced CT

ASCO recommends CT of the chest and upper abdomen with IV contrast as the initial staging examination for pleural mesothelioma.

CT helps evaluate:

• pleural disease extent;
• chest-wall and mediastinal structures;
• regional lymph nodes;
• pleural fluid;
• suspicious disease outside the primary hemithorax.

If chest/upper-abdominal CT or PET/CT identifies abnormalities suspicious for abdominal metastatic disease, ASCO recommends further dedicated abdominal imaging when appropriate. Our imaging tests guide covers CT, PET, and MRI in more detail.

FDG PET/CT

ASCO recommends FDG PET/CT for initial staging, although it may be omitted in people who are not being considered for definitive surgical resection.

PET/CT can help identify disease that was not obvious on conventional imaging and can change the estimated extent of cancer.

An abnormal PET finding does not automatically confirm metastatic disease. The need for additional tissue confirmation depends on whether the result would alter management.

MRI

MRI with contrast can be used selectively when more detail is needed regarding structures such as the:

• diaphragm;
• chest wall;
• mediastinum.

How Is Stage 4 Mesothelioma Treated?

Treatment of Stage IV pleural mesothelioma generally focuses on systemic therapy, symptom management, and supportive care.

No single regimen is appropriate for all patients.

Treatment decisions can depend on:

• epithelioid versus nonepithelioid histology;
• performance status;
• heart, lung and kidney function;
• autoimmune disease or other contraindications to immunotherapy;
• previous treatment;
• disease burden;
• symptoms;
• treatment goals;
• patient preferences.

ASCO recommends systemic therapy for eligible pleural mesothelioma patients, as it can improve survival and quality of life. Our treatment guide covers these approaches across all stages.

Immunotherapy for Stage 4 Mesothelioma

Nivolumab Plus Ipilimumab — Nivolumab plus ipilimumab is an established first-line systemic treatment option for newly diagnosed pleural mesothelioma. The FDA-approved indication is specifically first-line treatment of adults with unresectable malignant pleural mesothelioma. ASCO recommends nivolumab plus ipilimumab as a first-line systemic option and gives it particular importance in patients with nonepithelioid disease.

In CheckMate 743, nivolumab plus ipilimumab improved overall survival compared with platinum-pemetrexed chemotherapy in previously untreated unresectable pleural mesothelioma. The difference was especially marked in the nonepithelioid subgroup, which historically responds poorly to chemotherapy.

Treatment choice remains individualized, as immune checkpoint inhibitors can cause significant immune-related toxicities and may not be suitable for all patients.

Pembrolizumab Plus Platinum-Pemetrexed — A second contemporary first-line approach combines pembrolizumab + pemetrexed + platinum chemotherapy. In September 2024, the FDA approved this combination for first-line treatment of adults with unresectable advanced or metastatic malignant pleural mesothelioma.

Approval was based on KEYNOTE-483. The trial showed a statistically significant overall-survival improvement for pembrolizumab plus chemotherapy compared with chemotherapy alone in patients with unresectable advanced or metastatic disease.

ASCO also identifies this chemoimmunotherapy regimen as a first-line option for newly diagnosed pleural mesothelioma across epithelioid and nonepithelioid histologies.

Stage IV status alone does not determine whether pembrolizumab-based chemoimmunotherapy or nivolumab/ipilimumab is preferable. The decision should be individualized.

Chemotherapy for Stage 4 Mesothelioma

Platinum-based chemotherapy with pemetrexed remains an established systemic treatment option, particularly for patients with epithelioid histology.

Common platinum options include:

• cisplatin;
• carboplatin when cisplatin is not appropriate.

ASCO states that carboplatin may be substituted for cisplatin in patients unable to tolerate cisplatin.

Pemetrexed + Platinum ± Bevacizumab — For patients with epithelioid histology, ASCO states that pemetrexed plus platinum-based chemotherapy, with or without bevacizumab in appropriately selected patients, may be offered as a first-line systemic treatment option. Bevacizumab is not suitable for all patients. Cardiovascular disease, uncontrolled hypertension, bleeding or clotting risk, performance status, age, and other clinical factors must be considered.

Nonepithelioid Disease — For previously untreated nonepithelioid pleural mesothelioma, current ASCO guidance states that chemotherapy alone generally should not be offered unless there is a medical contraindication to immunotherapy. Accurate histology identification is essential before selecting systemic treatment.

Treatment After Disease Progression

Treatment may continue after the initial regimen is no longer effective.

ASCO lists several potential later-line approaches depending on what treatment a patient has already received.

For example, patients previously treated with first-line immunotherapy may be considered for pemetrexed plus platinum-based chemotherapy, with or without bevacizumab in appropriate circumstances. In patients who have received both immunotherapy and pemetrexed-platinum chemotherapy, current ASCO guidance allows options such as vinorelbine or gemcitabine, with gemcitabine plus ramucirumab among the later-line approaches that may be considered.

The appropriate sequence depends heavily on:

• previous response;
• treatment toxicity;
• performance status;
• comorbidities;
• histology;
• available clinical trials.

Specialist oncology input is especially valuable in this context.

Is Surgery Used for Stage 4 Mesothelioma?

Maximal surgical cytoreduction is generally not used as definitive treatment for Stage IV pleural mesothelioma, as Stage IV is defined by distant metastatic disease.

ASCO recommends restricting maximal cytoreductive surgery to highly selected patients with favorable characteristics, such as early-stage T1–T3 N0 epithelioid disease, and no evidence of extrathoracic disease.

Stage IV M1 disease does not meet these criteria.

This does not mean that no procedure can ever be useful.

Procedures may still be performed to:

• manage pleural effusion;
• relieve symptoms;
• obtain diagnostic tissue;
• address selected complications.

These are different from maximal cytoreductive surgery intended to remove macroscopic pleural tumor.

Radiation Therapy in Stage 4 Mesothelioma

Radiation therapy can be beneficial for selected symptomatic sites, even if it cannot address all metastatic disease.

ASCO supports palliative radiation approaches depending on the target location and surrounding organs.

Possible goals can include:

• reducing pain from a localized tumor;
• controlling a symptomatic chest-wall mass;
• treating a painful metastatic site;
• improving symptoms from a focal area of progression.

Radiation decisions depend on anatomy, prior treatments, expected benefit, toxicity, and overall treatment goals.

Radiation should not be considered a cure for Stage IV disease.

Managing Pleural Effusion

Pleural effusion can significantly contribute to breathlessness and discomfort.

For patients who are not candidates for maximal cytoreductive surgery, ASCO states that options for symptomatic pleural effusion can include:

• tunneled pleural catheter placement;
• pleurodesis through a chest tube or thoracoscopy;
• selected thoracoscopic procedures.

The optimal approach depends on fluid recurrence rate, lung expansion, symptoms, overall health, and other clinical factors.

The primary goal is symptom control and improved quality of life, rather than cancer eradication.

Palliative Care for Stage 4 Mesothelioma

Palliative care is not the same as discontinuing cancer treatment.

Palliative care is specialized support aimed at improving quality of life by managing symptoms and addressing psychological, social, and other challenges associated with serious illness. It can be provided alongside cancer-directed therapy.

For someone with Stage 4 mesothelioma, palliative care may help with:

• breathlessness;
• pain;
• fatigue;
• appetite and nutrition concerns;
• treatment side effects;
• sleep;
• emotional distress;
• practical and caregiver needs.

Palliative care can begin early, well before end-of-life care is required.

Palliative Care vs Hospice Care

Palliative care and hospice care are distinct and not interchangeable.

Palliative care can be provided alongside disease-directed treatment and can begin at essentially any point in a serious illness.

Hospice care is focused on comfort when life-prolonging or curative treatment is no longer the goal.

In the United States, hospice eligibility typically requires an estimated prognosis of six months or less if the illness follows its expected course. This is a hospice eligibility guideline, not a definition of Stage 4 mesothelioma or a prediction for every patient.

A Stage 4 diagnosis alone does not require immediate hospice enrollment.

Clinical Trials for Stage 4 Mesothelioma

Clinical trials are especially important in rare cancers such as pleural mesothelioma.

Depending on eligibility and prior treatment, studies may investigate:

• new immunotherapy combinations;
• therapies for tumors progressing after checkpoint inhibitors;
• new chemotherapy combinations;
• biomarker-directed approaches;
• novel systemic treatments;
• symptom and supportive-care strategies.

NCI maintains mesothelioma treatment-trial resources and notes that clinical trials may test new therapies, new uses of existing therapies, and supportive or palliative approaches.

Participation should be considered alongside standard treatment options, potential benefits, uncertainties, eligibility criteria, and possible risks.

Why Histology Matters in Stage 4 Mesothelioma

Stage refers to anatomical extent, while histology describes the microscopic tumor type.

They answer different questions.

Epithelioid Mesothelioma

Epithelioid mesothelioma generally has a more favorable prognosis than nonepithelioid disease and offers several reasonable first-line systemic approaches, depending on the patient. ASCO recognizes nivolumab/ipilimumab, platinum-pemetrexed chemotherapy in appropriate patients, and pembrolizumab/platinum/pemetrexed chemoimmunotherapy as options within contemporary treatment planning.

Biphasic and Sarcomatoid Mesothelioma

Biphasic and sarcomatoid tumors are collectively considered nonepithelioid in many treatment discussions.

ASCO recommends nivolumab plus ipilimumab as the preferred first-line approach for previously untreated nonepithelioid disease when immunotherapy is not contraindicated.

This distinction is clinically important: two patients with the same Stage IV classification may receive different treatment recommendations based on their histology and medical circumstances.

Stage 4 Mesothelioma Prognosis

Stage IV pleural mesothelioma is advanced metastatic disease, and prognosis is generally less favorable than for disease diagnosed before distant metastasis.

However, stage is only one factor influencing prognosis.

The NCI identifies several factors that can influence mesothelioma outcome, including:

• stage;
• tumor extent;
• histology;
• age;
• performance status;
• overall health;
• heart and lung health;
• amount of pleural fluid;
• blood-count parameters;
• whether disease is newly diagnosed or recurrent.

Response to treatment also varies substantially between individuals.

For this reason, no population statistic can accurately predict how long one specific person will live. Our prognosis guide discusses these factors across all stages.

Stage 4 Mesothelioma Life Expectancy

There is no single medically reliable life-expectancy figure for every person with Stage 4 mesothelioma.

You may see websites claiming:

“Stage 4 life expectancy is X months.”

Such figures can be misleading, as they may combine:

• different staging editions;
• different histologic subtypes;
• patients treated in different eras;
• different performance-status groups;
• different systemic therapies;
• newly diagnosed and recurrent disease.

Version 9 changed pleural mesothelioma stage groupings, so older stage-specific literature should be interpreted carefully.

Individual prognosis should be discussed with the treating oncology team, based on the actual clinical situation rather than generic online statistics.

Stage 4 Mesothelioma Survival Rate

Current American Cancer Society data provide survival by SEER Summary Stage, not by AJCC Stage IV.

For pleural mesothelioma, the ACS currently reports a 5-year relative survival rate of 11% for SEER “distant” disease.

However, this statistic needs an important qualification:

SEER distant disease is not the same classification system as AJCC Version 9 Stage IV.

SEER uses:

• localized;
• regional;
• distant.

AJCC uses TNM categories and Stage I–IV groupings.

Therefore, the 11% figure should not be relabeled as “the Stage 4 survival rate.”

ACS notes that these statistics are based on patients diagnosed in earlier years and may not fully reflect newer treatments.

Can Stage 4 Mesothelioma Be Cured?

Stage IV pleural mesothelioma is generally not curable with current standard treatments.

Treatment is typically directed toward:

• controlling cancer;
• slowing progression;
• prolonging survival when possible;
• relieving symptoms;
• preserving function;
• maintaining quality of life.

Modern systemic treatments can provide meaningful disease control for some patients, but neither immunotherapy nor chemotherapy guarantees a cure.

ASCO recommends systemic therapy for appropriate patients, as it can improve survival and quality of life.

Is Stage 4 Mesothelioma Terminal?

Stage 4 is advanced metastatic cancer and is generally not curable, but “terminal” is not a treatment plan.

A Stage IV diagnosis does not automatically preclude cancer-directed therapy, clinical trials, symptom-directed radiation, pleural procedures, or specialist palliative care.

Some patients are eligible for first-line and subsequent systemic treatments, while others may require comfort-focused care due to medical conditions, cancer burden, or declining performance status.

ASCO notes that selected patients with poor performance status may be better served by limited palliative treatment or palliative care, with the decision individualized to their clinical condition.

Hospice is considered when care goals shift entirely to comfort and the patient meets eligibility criteria.

Why a Mesothelioma Specialist Matters

Stage IV treatment now involves more than a choice between “chemotherapy” and “no treatment.”

Current management may involve decisions among:

• nivolumab/ipilimumab;
• pembrolizumab/platinum/pemetrexed;
• platinum-pemetrexed-based treatment;
• selected use of bevacizumab;
• later-line systemic treatments;
• clinical trials;
• radiation;
• pleural procedures;
• palliative care.

ASCO guidelines emphasize individualized treatment based on histology, performance status, medical contraindications, and prior therapy.

Because pleural mesothelioma is rare, specialist pathology and multidisciplinary review are valuable. The NCI notes that a second opinion can help confirm diagnosis and treatment planning. Our find a specialist guide can help with that search.

What to Do After a Stage 4 Diagnosis

Questions worth discussing with the treating team include:

1. Was my disease staged using AJCC/UICC Version 9?
2. What finding established M1 disease?
3. Where has metastatic disease been identified?
4. Does any suspicious metastatic site need additional confirmation?
5. What is my histologic subtype?
6. Has a mesothelioma-experienced pathologist reviewed my pathology?
7. What is my performance status?
8. Am I a candidate for nivolumab plus ipilimumab?
9. Am I a candidate for pembrolizumab plus pemetrexed and platinum chemotherapy?
10. Would platinum-pemetrexed chemotherapy be appropriate for my histology?
11. Does bevacizumab have a role in my situation?
12. What treatment side effects are most relevant to my other medical conditions?
13. What would we use if the first treatment stops working?
14. Are there clinical trials appropriate for my treatment history?
15. Does my pleural effusion need drainage, pleurodesis, or a tunneled catheter?
16. Could radiation help with a specific painful or symptomatic site?
17. When should palliative care become part of my treatment team?
18. What symptoms should prompt an urgent call to my oncology team?
19. Would a second opinion at a mesothelioma center be useful?
20. What are the realistic goals of treatment in my individual case?

Our patient resources hub and financial assistance guide cover practical support options for patients and families.

Frequently Asked Questions

What is Stage 4 mesothelioma?

Under AJCC/UICC TNM Version 9, Stage IV diffuse pleural mesothelioma is Any T, Any N, M1. The defining feature is distant metastatic disease.

Does Stage 4 always mean the primary tumor is T4?

No. Stage IV can have any T category. M1 is what establishes Stage IV.

Is T4 mesothelioma always Stage 4?

No. T4 Any N M0 is Stage IIIB under Version 9. Stage IV requires M1.

Does spread to the opposite pleura always mean Stage 4?

Not automatically. TNM Version 9 lists direct extension to the contralateral pleura as a T4 feature. T4 with M0 is Stage IIIB. Separate distant metastatic involvement can instead represent M1 disease, so the pattern needs clinical interpretation.

Where can Stage 4 mesothelioma spread?

Examples include distant lymph nodes, bones, liver, peritoneum, the opposite lung or pleural region when metastatic, and other distant organs.

Is Stage 4 mesothelioma treatable?

Yes. Although Stage IV is generally not considered curable, systemic therapy and symptom-directed care can still be appropriate. ASCO recommends systemic treatment for eligible patients because it can improve survival and quality of life.

What immunotherapy is used for Stage 4 mesothelioma?

Nivolumab plus ipilimumab is an established first-line option for unresectable pleural mesothelioma. Pembrolizumab combined with pemetrexed and platinum chemotherapy is also FDA-approved as first-line therapy for unresectable advanced or metastatic malignant pleural mesothelioma.

Is immunotherapy better than chemotherapy?

There is no universal answer. Histology matters. ASCO particularly favors nivolumab/ipilimumab for previously untreated nonepithelioid disease, while several first-line options can be reasonable for epithelioid disease. Individual medical factors and treatment goals also matter.

Can Stage 4 mesothelioma be operated on?

Maximal surgical cytoreduction is generally not appropriate for Stage IV M1 disease because ASCO restricts this surgery to highly selected patients without extrathoracic disease and with favorable characteristics. Procedures can still be used for diagnosis or symptom relief.

Can radiation be used in Stage 4?

Yes, in selected situations. Palliative radiation can be used to treat specific symptomatic areas, such as a painful focal tumor site.

What is the Stage 4 mesothelioma survival rate?

There is no single current AJCC Version 9 Stage IV survival percentage that accurately predicts an individual outcome. ACS reports 11% 5-year relative survival for SEER distant pleural mesothelioma, but SEER distant and AJCC Stage IV are not identical classifications.

What is the life expectancy for Stage 4 mesothelioma?

There is no single reliable number for all patients. Prognosis varies with histology, age, performance status, overall health, disease burden, treatment, and treatment response.

Is Stage 4 mesothelioma terminal?

Stage IV is advanced metastatic disease and generally is not considered curable, but treatment may still be appropriate. Decisions about systemic therapy, clinical trials, palliative treatment or hospice depend on the person’s condition and treatment goals rather than the stage label alone.

Is palliative care the same as hospice?

No. Palliative care can be given alongside cancer-directed treatment. Hospice is focused on comfort when disease-directed curative or life-prolonging treatment is no longer the goal.

Should someone with Stage 4 mesothelioma get a second opinion?

A second opinion can be useful, particularly in a rare cancer where pathology, histology, and treatment sequencing can materially affect the plan. The NCI specifically notes that second opinions can help confirm diagnosis and treatment planning.

Medical References

1. American Joint Committee on Cancer. Diffuse Pleural Mesothelioma. AJCC Cancer Staging System, Version 9. American College of Surgeons; 2024.
2. NHS England / National Disease Registration Service. Pleural Mesothelioma — TNM 9th Edition Staging Guidance. Updated January 16, 2026.
3. American Cancer Society. Stages of Mesothelioma. Revised February 3, 2026.
4. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43:1006–1038. doi:10.1200/JCO-24-02425.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 2.2026.
6. National Cancer Institute. Mesothelioma Diagnosis & Prognosis. Updated May 16, 2025.
7. National Cancer Institute. Treatment for Mesothelioma. Updated May 16, 2025.
8. National Cancer Institute. Malignant Mesothelioma Treatment (PDQ®) — Health Professional Version.
9. U.S. Food and Drug Administration. Nivolumab plus ipilimumab approval for first-line treatment of adults with unresectable malignant pleural mesothelioma.
10. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. September 17, 2024.
11. American Cancer Society. Survival Rates for Pleural Mesothelioma. Revised February 3, 2026.
12. National Cancer Institute. Palliative Care in Cancer.

Editorial and Medical Review Information

Stage 3 pleural mesothelioma is an advanced stage of malignant pleural mesothelioma in which the cancer has grown more extensively within the chest and/or reached regional lymph nodes, but distant metastasis has not been identified.

Under the current American Joint Committee on Cancer (AJCC) Version 9 TNM staging system, Stage 3 is divided into Stage IIIA and Stage IIIB. This distinction matters because the extent of the tumor, lymph-node involvement, overall health, and whether the disease is considered resectable can influence treatment planning.

A diagnosis of Stage 3 does not indicate that all treatment options have been exhausted. Selected patients with Stage IIIA disease may be considered for surgery within a multimodality treatment approach. Conversely, systemic therapies such as immunotherapy and chemotherapy are key options for unresectable disease. A multidisciplinary team with expertise in pleural mesothelioma should conduct treatment planning.

Stage 3 Mesothelioma at a Glance

What Does Stage 3 Mesothelioma Mean?

The stage of pleural mesothelioma describes the anatomical extent of the cancer at the time it is assessed. Doctors use three main categories:

• T — Tumor: the extent of the primary pleural tumor.
• N — Nodes: whether cancer has reached regional lymph nodes.
• M — Metastasis: whether cancer has spread to distant sites.

These categories are combined into an overall stage. For Stage 3 pleural mesothelioma, the disease remains M0, meaning distant metastasis has not been identified. The distinction between Stage IIIA and IIIB is based on the T and N categories. See our mesothelioma stages overview for how Stage 3 relates to the full AJCC staging system.

AJCC Version 9 Stage 3 Groups

This Version 9 classification is important because older articles may describe lymph-node involvement differently. Under the current system, N2 disease can still be classified as Stage IIIA. Stage IIIB is defined by a T4 primary tumor, regardless of the regional N category, as long as distant metastasis is absent.

Stage 3A vs Stage 3B Mesothelioma

Stage IIIA and Stage IIIB are both advanced forms of pleural mesothelioma, but they are not interchangeable.

Stage 3A Mesothelioma

Stage IIIA can result from several combinations of tumor extent and lymph-node involvement. It includes:

• T2 disease with N1 lymph-node involvement;
• T3 disease with N0 or N1 nodes; or
• T1, T2, or T3 disease with N2 lymph-node involvement.

In Version 9, N1 generally describes regional lymph nodes on the same side as the primary tumor, while N2 includes contralateral mediastinal lymph nodes and supraclavicular lymph nodes on either side.

Some people with Stage IIIA mesothelioma may still have disease considered potentially resectable. However, the stage alone does not determine whether surgery is appropriate.

Stage 3B Mesothelioma

Stage IIIB corresponds to: T4, any N, M0.

T4 means the primary tumor has extended into structures in a way that generally makes complete surgical removal unrealistic. Examples can include extensive invasion involving structures such as the chest-wall bone, mediastinal organs, opposite pleura, or tumor extending through the diaphragm or pericardium. The cancer can have any regional lymph-node status, but there is still no distant metastasis.

Stage Does Not Equal Resectability

One of the most important concepts to understand about Stage 3 mesothelioma is that stage and resectability are related but not identical.

Resectability asks a different question: can the visible tumor reasonably be removed with surgery while maintaining an acceptable balance between potential benefit and risk?

The American Cancer Society notes that some Stage 3 pleural mesotheliomas may still be considered resectable, although there are important exceptions. Factors influencing this assessment include tumor location and extent, histologic subtype, lymph-node involvement, and whether the person is medically fit enough for major thoracic surgery.

Therefore, evaluation at a specialized mesothelioma center is recommended before determining the feasibility of specific treatment options. Our find a specialist guide can help with that search.

What Are the Symptoms of Stage 3 Mesothelioma?

No symptom proves a person has Stage 3 rather than another stage. Staging is determined through imaging, pathology, and other clinical information, not symptoms alone.

However, as pleural tumors become more extensive, symptoms may become more noticeable. Possible symptoms include:

• shortness of breath;
• chest pain or pressure;
• persistent cough;
• fatigue;
• reduced exercise tolerance;
• loss of appetite;
• unintended weight loss;
• pleural effusion, or fluid around the lung;
• discomfort related to chest-wall involvement.

Symptoms vary substantially from one person to another. Their severity does not always correspond directly to cancer stage. A person with substantial disease can sometimes have relatively modest symptoms, while another person with less extensive disease may experience significant breathlessness or pain.

New or worsening symptoms should be reported to the treating medical team for assessment, rather than being used to estimate cancer stage independently. Our symptoms guide covers the broader range of possible signs.

How Is Stage 3 Mesothelioma Diagnosed?

A diagnosis of Stage 3 pleural mesothelioma generally involves two separate steps: confirming that the tumor is mesothelioma, and determining how far the disease has spread. Our diagnosis guide and tests and biopsy guide cover this process in more detail.

Biopsy and Pathology

A tissue biopsy is typically needed to establish a definitive diagnosis. The pathology assessment helps determine whether malignant mesothelioma is present and identifies the histologic subtype, such as:

• epithelioid;
• biphasic;
• sarcomatoid.

Histology is important because tumor biology can influence prognosis and treatment planning.

CT Imaging

Contrast-enhanced CT imaging can help assess pleural tumor distribution, pleural thickness, involvement of neighboring structures, lymph nodes, pleural effusion, and possible disease elsewhere in the chest. AJCC Version 9 also incorporates quantitative assessment of pleural thickness, known as Psum, into the T classification. Our imaging tests guide covers CT, PET, and MRI in more detail.

PET/CT

PET/CT may provide additional information about metabolically active disease and can help identify suspicious lymph nodes or possible disease outside the primary pleural region. An abnormal PET finding does not by itself prove mesothelioma spread; biopsy or additional assessment may sometimes be needed.

MRI

MRI can be useful in selected patients when doctors need additional detail about local tumor extension, particularly around structures such as the diaphragm, chest wall, or mediastinum.

Lymph-Node Evaluation

Because lymph-node status affects staging, additional sampling may sometimes be recommended. Depending on the clinical situation, assessment can involve techniques such as endobronchial ultrasound-guided sampling, endoscopic ultrasound-guided sampling, mediastinoscopy, or surgical lymph-node sampling. Not all patients require every diagnostic test; the staging workup should be tailored to the individual clinical scenario.

Clinical Stage vs Pathologic Stage

A person may initially receive a clinical stage based on imaging, biopsy results, examination, and other tests. If surgery is performed, doctors may obtain additional information directly from the chest and from surgically removed tissue. This can produce a pathologic stage. The pathologic stage can sometimes differ from the clinical stage because surgery may reveal disease that was not clearly visible on preoperative imaging.

How Is Stage 3 Mesothelioma Treated?

There is no single treatment plan that is appropriate for every person with Stage 3 mesothelioma. Treatment depends on factors such as Stage IIIA versus IIIB, whether the tumor is resectable, histologic subtype, lymph-node involvement, previous treatment, age and overall health, lung and heart function, symptoms, treatment goals, and patient preferences.

A multidisciplinary mesothelioma team may include thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, palliative-care specialists, and other professionals. Our treatment guide covers these approaches across all stages.

Surgery for Stage 3 Mesothelioma

Surgical cytoreduction is not routinely recommended for all patients with Stage 3 disease. It may be considered for highly selected patients with favorable features after comprehensive staging and multidisciplinary review, particularly some people with Stage IIIA disease.

When surgical cytoreduction is appropriate, lung-sparing approaches such as pleurectomy/decortication are generally favored when feasible. Extrapleural pneumonectomy is reserved for highly selected patients at experienced mesothelioma centers.

Surgery for mesothelioma is complex and is generally considered as part of a broader multimodality strategy rather than as an isolated treatment. Not every Stage IIIA tumor is surgically removable, and being technically resectable does not automatically mean surgery offers the best risk-benefit balance for a particular patient.

Stage IIIB disease is generally considered unresectable because the T4 tumor has invaded structures that prevent complete macroscopic resection.

Consultation at a high-volume mesothelioma center is recommended when surgical intervention is under consideration.

Immunotherapy

Immune checkpoint inhibitors have become an important part of treatment for unresectable malignant pleural mesothelioma.

Nivolumab Plus Ipilimumab — The FDA has approved nivolumab plus ipilimumab as first-line treatment for adults with unresectable malignant pleural mesothelioma. These medications target immune checkpoints and are intended to help the immune system recognize and attack cancer cells more effectively. Whether this combination is appropriate depends on the person’s overall clinical situation and treatment history.

Chemotherapy

Platinum-based chemotherapy combined with pemetrexed remains an important systemic treatment option for pleural mesothelioma. A platinum drug may include cisplatin or carboplatin. Chemotherapy can be used alone in selected situations or incorporated into a broader treatment strategy. The NCI lists systemic treatment among the principal approaches used for advanced mesothelioma.

Pembrolizumab Plus Chemotherapy — In September 2024, the FDA approved pembrolizumab combined with pemetrexed and platinum chemotherapy as first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma. The approval was based on the KEYNOTE-483 trial, which showed an improvement in overall survival for the pembrolizumab-plus-chemotherapy group compared with chemotherapy alone. This does not mean that pembrolizumab plus chemotherapy is automatically the preferred treatment for every person with Stage 3 disease. The choice among available systemic approaches depends on tumor characteristics, medical history, contraindications, previous treatment, expected toxicity, and patient preferences.

Radiation Therapy

Radiation therapy can have several possible roles in pleural mesothelioma care. Depending on the clinical situation, it may be considered as part of selected multimodality approaches, for local disease control, to relieve cancer-related pain, or to manage symptoms caused by a specific tumor site. Radiation planning in pleural mesothelioma can be technically complex because of the proximity of the lungs, heart, esophagus, spinal cord, and other critical structures.

Multimodality Treatment

Because pleural mesothelioma often grows along pleural surfaces rather than forming a single well-defined mass, treatment frequently involves more than one modality. For selected patients, a plan might incorporate different combinations of systemic therapy, surgery, and radiation therapy. The sequence and combination should be individualized. The term “multimodality treatment” does not imply that all patients should undergo every available therapy — the potential benefit of an intensive strategy must always be weighed against its risks.

Palliative and Supportive Care

Palliative care is distinct from hospice care and does not signify discontinuation of cancer treatment. Palliative care focuses on reducing symptoms, preserving function, and improving quality of life, and it can be provided at the same time as active anticancer treatment.

For pleural mesothelioma, supportive interventions may address problems such as breathlessness, pleural fluid accumulation, chest pain, fatigue, appetite problems, anxiety or distress, and sleep difficulties. Management of recurrent pleural effusion may include drainage procedures or pleurodesis in appropriate cases. Radiation therapy can also sometimes be used to relieve localized cancer-related pain. The NCI includes symptom-directed and palliative treatment among the options for advanced mesothelioma.

Clinical Trials for Stage 3 Mesothelioma

Clinical trials are an important consideration in a rare cancer such as mesothelioma. Trials may evaluate new immunotherapy combinations, different sequences of systemic therapy, novel targeted approaches, new radiation strategies, perioperative treatments, and biomarkers that may help select therapy.

Eligibility depends on factors such as stage, histology, previous treatments, performance status, organ function, and specific trial criteria. A mesothelioma specialist can assist in determining eligibility for appropriate clinical trials.

Stage 3 Mesothelioma Prognosis

Stage is important, but it is only one part of prognosis. Outcome can also be influenced by histologic subtype, performance status, age and general health, extent of tumor involvement, lymph-node status, whether disease can be resected, response to treatment, laboratory findings, and other medical conditions. The American Cancer Society identifies factors such as functional status and epithelioid histology among variables associated with prognosis in addition to stage. Our prognosis guide discusses these factors across all stages.

How Long Can Someone Live With Stage 3 Mesothelioma?

There is no single reliable life-expectancy number that applies to every person with Stage 3 mesothelioma. Published studies involve different staging editions, patient populations, histologic subtypes, treatments, surgical selection criteria, and periods of diagnosis. As a result, providing a single “Stage 3 life expectancy” figure may be misleading.

Population survival statistics also cannot predict how long a person will live. For example, commonly cited SEER survival categories use localized, regional, and distant disease, which are not identical to AJCC Stage I, II, III, and IV. Those categories should not simply be relabeled as “Stage 3 survival.”

A specialist with knowledge of the patient’s imaging, pathology, overall health, and treatment response can offer a more individualized and meaningful prognosis discussion.

Can Stage 3 Mesothelioma Be Cured?

Mesothelioma remains a difficult cancer to cure. For most people with advanced pleural mesothelioma, treatment aims to control the disease, prolong survival when possible, reduce symptoms, and maintain quality of life. However, Stage 3 covers a heterogeneous group of patients. Some carefully selected people with potentially resectable Stage IIIA disease may undergo intensive multimodality treatment. It is more appropriate to discuss treatment goals and realistic outcomes on an individual basis, rather than assuming uniform prognosis for all Stage 3 diagnoses.

Is Stage 3 Mesothelioma Terminal?

A Stage 3 diagnosis is serious, but the term terminal does not accurately describe every person at the time of diagnosis. Stage 3 means the cancer is advanced locally and/or regionally but has not met the criteria for distant metastatic Stage 4 disease. Patients may still receive active treatment including systemic therapy, symptom-directed treatment, clinical-trial therapy, and, for selected patients, surgery-based approaches. The treating oncology team is best equipped to determine whether treatment is intended for disease control, symptom relief, long-term remission, or other specific objectives.

Stage 3 vs Stage 4 Mesothelioma

The most important distinction is distant metastasis.

Stage 4 pleural mesothelioma is defined by M1 disease, regardless of the T or N category. See our Stage 4 mesothelioma guide for more detail.

What to Do After a Stage 3 Diagnosis

A Stage 3 diagnosis can generate many decisions in a short period of time. Useful questions for the oncology team include:

1. Is this Stage IIIA or Stage IIIB under AJCC Version 9?
2. What are my exact T, N, and M categories?
3. Has the pathology been reviewed by a pathologist experienced in mesothelioma?
4. What is my mesothelioma histologic subtype?
5. Is additional lymph-node staging needed?
6. Is the disease considered resectable or unresectable?
7. Should I obtain an opinion from a mesothelioma treatment center?
8. What systemic treatment options are appropriate for me?
9. Is surgery worth considering in my case?
10. Are there clinical trials for which I may qualify?
11. How will symptoms such as breathlessness, pain, or pleural effusion be managed?
12. What are the goals, expected benefits, and major risks of each treatment option?

Obtaining a second opinion is particularly valuable in cases of uncertainty regarding resectability, pathology, or optimal treatment sequencing. Our find a specialist guide can help locate an experienced mesothelioma center.

Frequently Asked Questions

What is Stage 3 mesothelioma?

Stage 3 pleural mesothelioma is advanced disease that has spread more extensively within the chest and/or to regional lymph nodes but has not spread to distant sites. Under AJCC Version 9, it is divided into Stage IIIA and IIIB.

What is the difference between Stage 3A and Stage 3B mesothelioma?

Stage IIIA includes several combinations of T1–T3 tumors and regional lymph-node involvement. Stage IIIB is T4, any N, M0. Stage IIIB therefore reflects extensive local tumor invasion rather than simply “more lymph-node spread.”

Can Stage 3 mesothelioma be operated on?

Some people with Stage IIIA disease may be candidates for surgery, but many are not. Resectability depends on anatomy, tumor biology, lymph nodes, general health, and evaluation by an experienced multidisciplinary team. Stage IIIB/T4 disease is generally considered unresectable.

Has Stage 3 mesothelioma spread to distant organs?

No. Stage 3 pleural mesothelioma remains M0. Evidence of distant metastasis would classify the disease as Stage 4 under AJCC Version 9.

What treatments are available for Stage 3 mesothelioma?

Depending on the individual case, treatment may include immunotherapy, platinum-pemetrexed chemotherapy, pembrolizumab with platinum-pemetrexed chemotherapy for eligible unresectable disease, surgery in carefully selected patients, radiation therapy, clinical trials, and palliative/supportive care.

Does Stage 3 automatically mean hospice?

No. Stage 3 patients may still receive active anticancer treatment. Palliative care can also be provided alongside treatment to control symptoms and improve quality of life.

Should I get a second opinion?

A second opinion may be particularly useful for a rare cancer such as mesothelioma, especially when surgery, clinical-trial participation, pathology interpretation, or the choice between systemic treatment strategies is being considered.

Medical References

1. American Joint Committee on Cancer. Malignant Pleural Mesothelioma. AJCC Cancer Staging System, Version 9. American College of Surgeons; 2024.
2. American Cancer Society. Stages of Mesothelioma. cancer.org, last revised February 3, 2026.
3. Kindler HL, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43:1006–1038. doi:10.1200/JCO-24-02425.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 2.2026.
5. National Cancer Institute. Mesothelioma Treatment. cancer.gov, updated May 16, 2025.
6. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. September 17, 2024.
7. U.S. Food and Drug Administration. Nivolumab plus ipilimumab prescribing information for unresectable malignant pleural mesothelioma.

Editorial and Medical Review Information

Stage 2 diffuse pleural mesothelioma is M0 disease, meaning no distant metastasis has been identified. It is more advanced than Stage 1 but does not meet the criteria for Stage 3 or distant metastatic Stage 4 disease.

According to the latest AJCC Version 9 TNM staging system, there are two ways someone can be diagnosed with Stage 2 pleural mesothelioma: T2 N0 M0 or T1 N1 M0.

This difference matters because Stage 2 does not always mean the cancer has reached the lymph nodes. You can have Stage 2 if the main tumor meets T2 criteria and the lymph nodes are clear, or if a T1 tumor has spread to N1 lymph nodes on the same side of the chest.

Some people with Stage 2 mesothelioma may be able to have more than one type of treatment, but the stage by itself does not decide if surgery is right. Doctors also look at the cancer type, lymph-node involvement, whether the tumor can be removed, heart and lung health, overall fitness, and what the patient wants.

Current ASCO guidance recommends surgical cytoreduction only for highly selected patients with favorable prognostic characteristics after comprehensive staging and multidisciplinary review.

Stage 2 Mesothelioma at a Glance

What Does Stage 2 Mesothelioma Mean?

Pleural mesothelioma staging uses the TNM system:

• T — Tumor: describes the primary pleural tumor.
• N — Nodes: describes regional lymph-node involvement.
• M — Metastasis: describes distant metastatic disease.

In Version 9, Stage II can arise in two different ways.

Stage 2 Group 1: T2 N0 M0

The primary tumor meets T2 criteria, but no regional lymph-node metastasis has been identified, and there is no distant metastasis.

Stage 2 Group 2: T1 N1 M0

The primary tumor still meets the more limited T1 criteria, but cancer has been identified in N1 regional lymph nodes on the same side of the chest. There is no distant metastasis.

So, Stage 2 is more complicated than just saying the cancer has grown a bit more than Stage 1.

Understanding T2 N0 M0

For clinical staging under Version 9, T2 can be assigned through tumor thickness or specific local features.

A clinically staged tumor can be T2 when it remains limited to the ipsilateral pleura and either:

• Psum is greater than 12 mm but no more than 30 mm, with or without certain local invasive features; or
• Psum is 12 mm or less, but there is qualifying fissural involvement, mediastinal fat invasion, or a solitary area of chest-wall soft-tissue invasion.

For fissural disease, the Version 9 clinical classification defines qualifying involvement using Fmax greater than 5 mm.

If the patient is T2 N0 M0, regional lymph-node involvement has not been identified, and distant metastatic disease is absent.

What Are Psum and Fmax?

Version 9 introduced a more quantitative approach to the clinical T category for pleural mesothelioma. Pleural mesothelioma often grows diffusely along pleural surfaces rather than forming a single spherical mass that can be measured with one diameter.

Psum

Psum is the sum of maximum pleural thickness measured on CT at three levels of the hemithorax: upper, middle, and lower.

The measurements are added:

Psum = pmax1 + pmax2 + pmax3

The Version 9 clinical classification uses these thresholds:

• T1: Psum ≤12 mm, provided T1 fissural criteria are also satisfied;
• T2: Psum >12 mm to ≤30 mm, or lower Psum with specified invasive features;
• T3: Psum >30 mm.

Fmax

Fmax is the maximum pleural tumor thickness measured along the interlobar fissures.

For clinical staging:

• Fmax ≤5 mm is compatible with cT1 when the other T1 criteria are met;
• Fmax >5 mm represents qualifying fissural involvement and can contribute to cT2 classification.

Doctors who are experienced in reading scans for pleural mesothelioma should review these measurements.

Understanding T1 N1 M0

Stage 2 can also occur when the primary tumor still meets T1 criteria, but cancer has spread to N1 regional lymph nodes.

For clinical T1, the disease is limited to the ipsilateral pleura, with Psum ≤12 mm and no qualifying fissural involvement, corresponding to Fmax ≤5 mm.

What Does N1 Mean?

Version 9 defines N1 as metastasis to ipsilateral intrathoracic lymph nodes.

These can include regional nodes such as ipsilateral: bronchopulmonary, hilar, subcarinal, paratracheal, aortopulmonary, paraesophageal, peridiaphragmatic, pericardial fat-pad, intercostal, and internal mammary nodes.

Therefore: T1 + N1 + M0 = Stage II. A patient does not need a T2 primary tumor to have Stage 2 disease.

Stage 1 vs Stage 2 Mesothelioma

Stage 1 and Stage 2 differ based on primary tumor characteristics or regional lymph-node involvement.

A key Version 9 change is that T1 N1 M0 is now classified as Stage II, so Stage 2 is not simply a larger Stage 1 tumor.

Stage 2 vs Stage 3 Mesothelioma

Stage 3 includes additional combinations of tumor extent and lymph-node involvement.

Under Version 9, Stage IIIA includes T2N1, T3 disease, and T1–T3 with N2 in the applicable groupings, while Stage IIIB is defined by T4 disease without distant metastasis.

A useful distinction is therefore:

Stage II: T2N0 or T1N1, M0
Stage III: more extensive local disease and/or different regional nodal combinations, still M0.

Neither Stage 2 nor Stage 3 means distant metastatic disease. See our Stage 3 mesothelioma guide for more detail.

What Are the Symptoms of Stage 2 Mesothelioma?

There is no set group of symptoms that separates Stage 2 from Stage 1 or Stage 3.

Possible symptoms of pleural mesothelioma can include:

• shortness of breath;
• chest pain or pressure;
• persistent cough;
• fatigue;
• reduced exercise tolerance;
• pleural effusion;
• decreased appetite;
• unintended weight loss.

Symptoms are not reliable for staging. Stage is determined by imaging, pathology, lymph-node assessment, and other clinical data.

A patient with early-stage disease may experience significant breathlessness due to pleural fluid, while another with more extensive tumor may initially have fewer symptoms. Our symptoms guide covers the broader range of possible signs.

How Is Stage 2 Mesothelioma Diagnosed?

Diagnosing Stage 2 pleural mesothelioma involves two related but separate tasks: confirming that the disease is pleural mesothelioma, and determining the anatomical extent of disease.

Current ASCO guidance recommends thoracentesis for initial evaluation when a symptomatic pleural effusion is present and strongly recommends adequate tissue diagnosis, particularly thoracoscopic biopsy when antineoplastic treatment is being planned. Our diagnosis guide and tests and biopsy guide cover this process in more detail.

Pleural Fluid Evaluation

If a patient has a symptomatic pleural effusion, thoracentesis can help relieve symptoms and obtain fluid for cytologic examination. However, treatment planning for mesothelioma often requires more tissue than fluid cytology provides, especially for accurate histologic classification and further pathology studies. ASCO strongly recommends thoracoscopic biopsy when cancer-directed treatment is planned and clinically feasible.

Biopsy and Pathology

A tissue specimen helps establish the diagnosis of mesothelioma, histologic subtype, and additional pathologic characteristics relevant to treatment. The major histologic categories are epithelioid, biphasic, and sarcomatoid.

Histology affects both prognosis and treatment. ASCO specifically advises against maximal surgical cytoreduction for histologically confirmed sarcomatoid mesothelioma.

Contrast-Enhanced CT

ASCO recommends CT of the chest and upper abdomen with IV contrast as the initial staging study for pleural mesothelioma. CT helps evaluate pleural tumor distribution, Psum, fissural involvement, adjacent structures, regional lymph nodes, pleural effusion, and possible disease outside the primary hemithorax. Our imaging tests guide covers CT, PET, and MRI in more detail.

PET/CT

ASCO recommends FDG PET/CT for initial staging, but it may be omitted in patients not considered for definitive surgical resection. PET/CT can help identify suspicious nodal or distant disease that could alter the treatment plan. An abnormal PET result is not always equivalent to pathologic confirmation, particularly when a finding would substantially alter a major treatment decision.

MRI

MRI may be useful when additional anatomical detail is needed to assess possible involvement of structures such as the diaphragm, chest wall, or mediastinum. ASCO lists MRI with contrast as an optional additional staging study when appropriate.

Lymph-Node Evaluation Is Especially Important in Stage 2

In Stage 2, accurate nodal assessment can significantly impact both staging and treatment decisions.

A T1 tumor with N0 is Stage I, but N1 is Stage II. Likewise, a T2 tumor with N0 is Stage II, but N1 is Stage IIIA.

For patients being considered for maximal surgical cytoreduction, ASCO recommends considering mediastinoscopy and/or endobronchial ultrasound when mediastinal nodes are enlarged or PET-avid. Therefore, treatment decisions should not rely solely on the appearance of the pleural tumor.

Clinical Stage vs Pathologic Stage

A clinical stage is determined before definitive surgery using information from imaging, biopsy, examination, and other staging procedures. If surgical cytoreduction is performed, examination of surgically obtained tissue can provide a pathologic stage. Clinical and pathologic stages may differ. ASCO specifically cautions that patients who appear to have clinical Stage I or II disease can be upstaged at surgery when more extensive tumor or lymph-node involvement is found.

An Important Version 9 Detail

Psum and Fmax are particularly important for the clinical T classification. The Version 9 pathologic T classification uses different anatomical criteria. For example, pT2 includes ipsilateral pleural tumor with specified involvement such as the fissure, ipsilateral lung parenchyma, or nontransmural diaphragm involvement. Clinical CT thresholds should not be used as substitutes for pathologic staging criteria.

Is Stage 2 Mesothelioma Resectable?

Some Stage 2 pleural mesotheliomas may be anatomically resectable, but Stage 2 does not automatically indicate surgery is appropriate.

This point is particularly important because Stage II contains two biologically and anatomically different groups: T2 N0 M0 and T1 N1 M0.

Current ASCO guidance says surgical cytoreduction should not be routinely offered simply because a tumor appears anatomically resectable. It should be limited to highly selected patients with favorable characteristics, specifically including clinical T1–T3 N0 epithelioid tumors, after comprehensive staging and multidisciplinary review.

This distinction has direct implications for Stage 2.

Stage 2 T2 N0

A patient with T2 N0 M0, epithelioid histology, adequate cardiopulmonary reserve, good functional status, and otherwise favorable characteristics can fall within the ASCO-defined group in which surgical cytoreduction may be considered.

Stage 2 T1 N1

A patient with T1 N1 M0 has Stage 2 disease, but the presence of N1 nodes means the patient does not meet the N0 component of ASCO’s favorable T1–T3 N0 surgical-selection group. This is one reason why the label “Stage 2” alone is insufficient to determine surgical candidacy.

How Is Stage 2 Mesothelioma Treated?

There is no universal treatment sequence for Stage 2 pleural mesothelioma. Treatment planning can depend on T2N0 versus T1N1, histologic subtype, technical resectability, cardiopulmonary fitness, performance status, age and comorbidities, prior treatment, and patient goals and preferences. Ideally, management should involve a multidisciplinary team experienced in pleural mesothelioma. Our treatment guide covers these approaches across all stages.

Surgery for Stage 2 Mesothelioma

Maximal surgical cytoreduction may be considered in highly selected patients, particularly those fitting favorable criteria such as clinical T1–T3 N0 epithelioid disease and adequate fitness for multimodality therapy. It should not be considered routine therapy for all Stage 2 patients.

Pleurectomy/Decortication

Pleurectomy/decortication (P/D) is a lung-sparing approach intended to remove macroscopic pleural tumor while preserving the lung. When maximal surgical cytoreduction is chosen, ASCO recommends lung-sparing approaches as the preferred option due to lower operative and long-term risks compared with non-lung-sparing surgery.

Extrapleural Pneumonectomy

Extrapleural pneumonectomy (EPP) is a more extensive operation that includes removal of the affected lung together with pleural and other adjacent tissues. ASCO states that EPP may be considered for highly selected patients at experienced centers, but lung-sparing approaches should generally be the first choice when maximal cytoreduction is pursued.

Sarcomatoid Histology

Patients with histologically confirmed sarcomatoid mesothelioma should not be offered maximal surgical cytoreduction under current ASCO guidance. Therefore, determining histologic subtype is essential before major surgical planning.

Even after maximal macroscopic cytoreduction, microscopic disease may remain. ASCO guidance states that maximal surgical cytoreduction alone is generally insufficient and should be part of a broader antineoplastic treatment strategy when appropriate. Treatment may involve combinations or sequences of surgery, systemic therapy, and radiation therapy in selected cases. The optimal treatment sequence should be individualized.

Chemotherapy

Platinum-based chemotherapy with pemetrexed remains an established systemic treatment option for pleural mesothelioma. In patients with epithelioid histology, pemetrexed plus platinum-based chemotherapy, with or without bevacizumab in appropriate patients, may be offered as a first-line systemic option. In newly diagnosed nonepithelioid disease, current ASCO guidance favors immunotherapy and recommends chemotherapy alone primarily when immunotherapy is contraindicated.

When surgery is part of the treatment plan, ASCO permits systemic chemotherapy to be given either before or after surgical cytoreduction and describes perioperative pemetrexed/platinum-based chemotherapy as an option within multimodality treatment. The platinum drug is commonly cisplatin or carboplatin. Treatment selection depends on renal function, performance status, comorbidities, potential toxicities, and the overall therapeutic strategy.

Immunotherapy

Immunotherapy is now an established part of systemic treatment for pleural mesothelioma. However, a Stage 2 diagnosis alone does not mean every patient should receive immunotherapy. Its role and timing depend on surgical approach, resectability, histology, contraindications, and other clinical factors.

Nivolumab Plus Ipilimumab

The FDA indication for nivolumab plus ipilimumab is the first-line treatment of adults with unresectable malignant pleural mesothelioma. ASCO also identifies nivolumab plus ipilimumab as an important first-line systemic option in newly diagnosed pleural mesothelioma, with a particularly important role in nonepithelioid histology. For potentially resectable Stage 2 patients, treatment plans should be individualized rather than automatically following unresectable-disease regimens.

Pembrolizumab Plus Platinum-Pemetrexed

In September 2024, the FDA approved pembrolizumab plus pemetrexed and platinum chemotherapy as first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma. The KEYNOTE-483 trial demonstrated an overall-survival benefit for the pembrolizumab-plus-chemotherapy regimen compared with chemotherapy alone in that population. This FDA indication does not mean every Stage 2 patient requires pembrolizumab.

Can Immunotherapy Be Used Before Surgery?

This area continues to evolve. ASCO states that neoadjuvant immunotherapy-based treatment may be offered as an option to surgical candidates, but rates the evidence as limited compared with established systemic therapy for unresectable disease. Currently, there is insufficient evidence for ASCO to recommend routine adjuvant immunotherapy after surgical cytoreduction. Therefore, neoadjuvant or perioperative immunotherapy should not be considered mandatory for Stage 2 treatment.

Radiation Therapy

Radiation therapy can have a role in selected pleural mesothelioma treatment strategies. After maximal surgical cytoreduction, ASCO states that adjuvant radiation may be associated with a decreased risk of local recurrence and may be offered to selected patients. Because treatment is technically complex, it should be delivered at experienced centers. Radiation can also be used for symptom control or treatment of specific local sites depending on the clinical situation.

Managing Pleural Effusion and Symptoms

Supportive treatment is appropriate at any stage when symptoms require attention. For patients who are not candidates for maximal surgical cytoreduction, ASCO allows management of symptomatic pleural effusion with options such as pleurodesis or tunneled pleural catheter placement.

For patients who remain candidates for maximal cytoreductive surgery, management should be coordinated with the surgical team because ASCO advises against tunneled pleural catheters in surgical candidates due to the risk of chest-wall tumor implantation.

Palliative care can be integrated with cancer-directed treatment to manage symptoms and quality of life. It does not mean that active treatment has ended.

Clinical Trials for Stage 2 Mesothelioma

Clinical trials are relevant for early, intermediate, and metastatic stages of disease. Depending on eligibility, studies may investigate neoadjuvant immunotherapy, perioperative systemic treatment, novel immunotherapy combinations, surgical strategies, radiation approaches, biomarkers, and methods of reducing recurrence.

ASCO notes that surgical cytoreduction should ideally be performed as part of multidisciplinary treatment and, when possible, within clinical trials at experienced centers.

Stage 2 Mesothelioma Prognosis

Stage contributes to prognosis but cannot predict an individual’s outcome alone. The NCI identifies several factors that can affect mesothelioma prognosis, including cancer stage, tumor extent, resectability, pleural fluid burden, age, activity/performance status, overall health and cardiopulmonary function, histologic cell type, blood-count parameters, and whether disease is newly diagnosed or recurrent.

Histology is particularly important. Epithelioid tumors generally have a more favorable prognosis than sarcomatoid or biphasic disease, and histology also influences surgical and systemic treatment decisions. Our prognosis guide discusses these factors across all stages.

Stage 2 Mesothelioma Life Expectancy

There is no single medically reliable life expectancy figure for all individuals with Stage 2 mesothelioma.

This is especially important in 2026, as AJCC Version 9 changed the composition of Stage II. Current Stage II includes both T2N0M0 and T1N1M0, so older studies may not reflect the same patient population.

Older online statements such as “Stage 2 life expectancy is X months” should therefore be interpreted cautiously unless they clearly identify the staging edition, histology, treatment era, surgical-selection criteria, patient population, and treatment received. Population-level data can describe groups but cannot predict individual patient outcomes.

SEER Statistics Are Not AJCC Stage 2 Statistics

SEER commonly categorizes cancer as localized, regional, or distant. These categories are useful for population statistics but do not directly correspond to AJCC Stages I, II, III, and IV. Therefore, a SEER “regional” survival statistic should not be relabeled as a “Stage 2 survival rate.” This distinction is especially important following the Version 9 stage-group changes.

Can Stage 2 Mesothelioma Be Cured?

Stage 2 is nonmetastatic disease, and some patients may be considered for aggressive multimodality treatment. However, pleural mesothelioma remains challenging to cure. Even after maximal macroscopic cytoreduction, microscopic disease may persist. This is why surgery alone is generally not considered sufficient.

Treatment goals may include achieving maximal disease control, delaying recurrence or progression, prolonging survival when possible, preserving function, controlling symptoms, and maintaining quality of life. No treatment should be presented as guaranteeing a cure.

Is Stage 2 Mesothelioma Terminal?

A Stage 2 diagnosis should not automatically be considered terminal. Under Version 9, Stage 2 remains M0, meaning distant metastatic disease has not been identified. Some patients can still be evaluated for multimodality treatment, including selected surgery-based strategies. Treatment goals and expected outcomes should be discussed individually with the treating team.

Why a Mesothelioma Specialist Matters

Stage 2 is particularly important to review carefully because the same overall stage can represent either T2N0 or T1N1. These two scenarios can lead to different treatment discussions, particularly regarding surgery.

A multidisciplinary mesothelioma team can help evaluate whether Version 9 staging has been applied correctly, Psum and Fmax measurements, pathology and histology, nodal status, technical resectability, surgical suitability, systemic-treatment options, and clinical-trial eligibility.

The NCI also notes that obtaining a second opinion can help confirm diagnosis and guide treatment planning in cancer care. Our find a specialist guide can help with that search.

What to Do After a Stage 2 Diagnosis

Useful questions for the treating team include:

1. Is my disease staged according to AJCC Version 9?
2. Am I T2N0M0 or T1N1M0?
3. What are my Psum and Fmax measurements?
4. Which lymph nodes have been evaluated?
5. Is additional nodal sampling necessary?
6. Has a mesothelioma-experienced pathologist reviewed my pathology?
7. What is my histologic subtype?
8. Is the disease technically resectable?
9. Am I an appropriate candidate for maximal surgical cytoreduction?
10. How does my N status affect surgical eligibility?
11. If surgery is considered, why is P/D or another procedure recommended?
12. Should systemic treatment be given before or after surgery?
13. Is immunotherapy appropriate in my situation?
14. What are the goals and major risks of each treatment option?
15. Should I seek an opinion at a high-volume mesothelioma center?
16. Are clinical trials available for my specific situation?
17. How will pleural effusion, pain, or breathlessness be managed?
18. What follow-up will be required after treatment?

Frequently Asked Questions

What is Stage 2 mesothelioma?

Under AJCC Version 9, Stage 2 pleural mesothelioma is either T2 N0 M0 or T1 N1 M0. It remains nonmetastatic disease.

Does Stage 2 mesothelioma always involve lymph nodes?

No. Stage II T2 N0 M0 has no identified regional lymph-node metastasis. Stage II T1 N1 M0 does involve ipsilateral regional lymph nodes.

Has Stage 2 mesothelioma metastasized?

No distant metastatic disease has been identified. Stage 2 is M0. Distant metastatic disease is M1 and Stage IV.

What does T2 mean in pleural mesothelioma?

For clinical Version 9 staging, T2 can reflect Psum greater than 12 mm but no more than 30 mm, or a lower Psum with qualifying local features such as fissural involvement, mediastinal fat invasion or a solitary chest-wall soft-tissue site.

What does N1 mean?

N1 represents metastasis to ipsilateral intrathoracic regional lymph nodes, which can include hilar, bronchopulmonary, mediastinal and other specified regional nodal stations on the same side.

Can Stage 2 mesothelioma be operated on?

Some patients can be considered for surgical cytoreduction, but Stage 2 alone is not enough to decide. Current ASCO guidance particularly identifies T1–T3 N0 epithelioid disease as favorable for considering maximal cytoreduction in highly selected patients.

Does T1 N1 Stage 2 have the same surgical implications as T2 N0 Stage 2?

Not necessarily. T2N0 remains within the N0 component of the ASCO favorable surgical-selection group, while T1N1 does not. A multidisciplinary specialist assessment is therefore important.

Is surgery automatically recommended for Stage 2?

No. ASCO specifically states that surgical cytoreduction should not be routinely offered solely because the tumor is anatomically resectable.

Which surgical approach is generally preferred?

When maximal surgical cytoreduction is chosen, ASCO recommends lung-sparing approaches such as P/D as the first choice when feasible; EPP is reserved for highly selected patients at centers of excellence.

Can immunotherapy be used for Stage 2 mesothelioma?

It can be part of treatment in appropriate clinical situations, but it is not automatically required because a patient is Stage 2. Treatment depends strongly on resectability, histology, systemic-treatment indication and overall strategy.

What is the life expectancy for Stage 2 mesothelioma?

There is no single Version 9 Stage 2 life-expectancy figure that accurately predicts an individual outcome. Current Stage II includes different T/N groupings than older editions, making many historical Stage 2 statistics difficult to apply directly.

Is Stage 2 mesothelioma curable?

Some Stage 2 patients can receive aggressive multimodality treatment, but mesothelioma remains difficult to cure, and recurrence can occur even after extensive therapy. Surgery alone is generally considered insufficient when maximal cytoreduction is undertaken.

Should I get a second opinion?

A second opinion can be useful in a rare cancer such as mesothelioma, particularly when there is uncertainty about pathology, lymph-node status, resectability or surgical treatment.

Medical References

1. American Joint Committee on Cancer. Diffuse Pleural Mesothelioma. AJCC Cancer Staging System, Version 9. American College of Surgeons; 2024.
2. American Cancer Society. Stages of Mesothelioma. Last revised February 3, 2026.
3. NHS England / National Disease Registration Service. Pleural Mesothelioma — TNM 9th Edition Staging Sheet. Updated January 16, 2026.
4. Kindler HL, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43:1006–1038. doi:10.1200/JCO-24-02425.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 2.2026.
6. National Cancer Institute. Mesothelioma Diagnosis & Prognosis. Updated May 16, 2025.
7. National Cancer Institute. Mesothelioma Treatment. Updated May 16, 2025.
8. U.S. Food and Drug Administration. Nivolumab plus ipilimumab approval for first-line unresectable malignant pleural mesothelioma.
9. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. September 17, 2024.

Editorial and Medical Review Information

Stage 1 pleural mesothelioma is the earliest stage in the current formal staging system for diffuse pleural mesothelioma. At this stage, the tumor remains limited to the pleura on one side of the chest, has not spread to regional lymph nodes, and has not metastasized to distant parts of the body.

Under the current American Joint Committee on Cancer (AJCC) Version 9 TNM staging system, Stage 1 pleural mesothelioma is defined as T1 N0 M0.

For the clinical T1 category, the tumor is limited to the ipsilateral pleura, the sum of pleural thickness measurements (Psum) is 12 mm or less, and there is no qualifying fissural involvement. There is also no regional lymph-node involvement (N0) and no distant metastasis (M0).

Importantly, AJCC Version 9 no longer divides Stage 1 pleural mesothelioma into Stage IA and Stage IB. Patients may still encounter those terms in older articles or records based on previous staging systems, but they should not be presented as current Version 9 Stage 1 categories.

Stage 1 disease may provide more treatment options compared to later-stage mesothelioma; however, treatment decisions are not based solely on stage. Other critical factors include histologic subtype, resectability, cardiopulmonary fitness, overall health, and patient preferences.

Stage 1 Mesothelioma at a Glance

What Does Stage 1 Mesothelioma Mean?

Cancer staging describes the anatomical extent of disease at the time it is evaluated. For pleural mesothelioma, doctors use the TNM system:

• T — Tumor: the extent and measurable characteristics of the primary pleural tumor.
• N — Nodes: whether regional lymph nodes contain cancer.
• M — Metastasis: whether cancer has spread to distant parts of the body.

Stage 1 is assigned when all three components meet the following criteria:

T1

The tumor is limited to the pleura on the same side of the chest as the primary disease. For clinical T1 (cT1) under AJCC Version 9: Psum is 12 mm or less; and there is no qualifying involvement of the interlobar fissure, with Fmax 5 mm or less.

N0

There is no identified spread to regional lymph nodes.

M0

There is no identified distant metastatic disease.

Together: T1 + N0 + M0 = Stage I. See our mesothelioma stages overview for how Stage 1 relates to the full AJCC staging system.

Stage 1A and Stage 1B: Are They Still Used?

Not in the current AJCC Version 9 staging system for diffuse pleural mesothelioma.

Older staging systems divided early pleural mesothelioma into categories such as Stage IA and Stage IB. That distinction should not be carried forward into current Version 9 descriptions. Under Version 9, the current stage grouping is simply Stage I — T1 N0 M0.

This distinction is important because individuals seeking information online may encounter content based on previous AJCC editions. When comparing staging information, it is essential to verify the version of the staging system being referenced.

What Is Psum?

Psum is one of the major changes introduced into the clinical T classification of pleural mesothelioma. Pleural mesothelioma does not always form a single round mass that can be measured in the same way as many other solid tumors — it often grows along pleural surfaces. AJCC Version 9 therefore incorporates measurements of pleural thickness on CT imaging.

Psum represents the sum of three measurements of maximum pleural thickness obtained from the upper chest, middle chest, and lower chest. These measurements are taken along the chest wall or mediastinal pleural surfaces. The three maximum measurements are added together:

Psum = pmax1 + pmax2 + pmax3

For clinical T1 disease: Psum ≤12 mm.

What Is Fmax?

Fmax describes the maximum thickness of pleural tumor involving the interlobar fissure. It is assessed on imaging, typically using sagittal CT images.

For clinical T1: Fmax ≤5 mm. More substantial fissural involvement can contribute to classification as T2 rather than T1.

The introduction of Psum and Fmax is important because it makes the Version 9 clinical T classification more quantitative than previous editions.

Stage 1 vs Stage 2 Mesothelioma

The distinction between Stage 1 and Stage 2 is not simply that the tumor is “slightly larger.” Stage 2 includes different combinations of tumor extent and lymph-node involvement.

A person with a relatively limited T1 tumor who has ipsilateral regional lymph-node involvement can therefore be classified as Stage 2. This illustrates why stage cannot be determined solely by tumor thickness. See our Stage 2 mesothelioma guide for more detail.

What Are the Symptoms of Stage 1 Mesothelioma?

Stage 1 mesothelioma does not have a unique set of symptoms. Some people can have relatively subtle symptoms at an early stage, while others may already experience significant discomfort.

Possible symptoms include:

• shortness of breath;
• chest pain or pressure;
• persistent cough;
• fatigue;
• reduced exercise tolerance;
• pleural effusion, or fluid around the lung;
• unexplained weight loss;
• decreased appetite.

These symptoms are nonspecific and may also occur in various other respiratory or medical conditions. Symptoms alone cannot reliably indicate the cancer stage. A person with Stage 1 disease can have substantial symptoms because of a pleural effusion, while another person with more extensive disease might initially report fewer symptoms. Staging requires imaging, pathology, and clinical assessment. Our symptoms guide covers the broader range of possible signs.

How Is Stage 1 Mesothelioma Diagnosed?

Diagnosing Stage 1 pleural mesothelioma requires answering two separate questions: is the disease truly mesothelioma, and how far has it spread? A staging classification should not substitute for a definitive pathologic diagnosis. Our diagnosis guide and tests and biopsy guide cover this process in more detail.

Initial Imaging

Chest imaging may first identify abnormalities such as pleural thickening, pleural nodularity, pleural effusion, pleural masses, or loss of normal pleural contours. Contrast-enhanced CT is particularly important for evaluating pleural tumor distribution and for clinical staging. Under Version 9, CT also plays a direct role in assigning the clinical T category because Psum and Fmax are imaging-based measurements. Our imaging tests guide covers CT, PET, and MRI in more detail.

Pleural Fluid Evaluation

If a patient presents with a symptomatic pleural effusion, thoracentesis may be performed both to relieve symptoms and to obtain fluid for cytologic evaluation. However, pleural-fluid cytology alone may not provide enough information to establish or subtype mesothelioma reliably in every patient. When antineoplastic treatment is planned, adequate tissue sampling is particularly important.

Biopsy and Pathology

A tissue biopsy is generally required for a definitive diagnosis. For patients in whom active cancer treatment is being considered, current ASCO guidance strongly supports obtaining adequate tissue, often through thoracoscopic biopsy when appropriate.

A tissue specimen allows the pathologist to confirm malignant mesothelioma, distinguish it from metastatic carcinoma and other pleural tumors, determine histologic subtype, perform appropriate immunohistochemical testing, and assess additional pathologic features that can influence treatment planning. The principal histologic patterns include epithelioid, biphasic, and sarcomatoid disease. Histology is especially important when considering surgery.

Epithelioid Mesothelioma

Epithelioid mesothelioma is the most common histologic subtype and is generally associated with a more favorable prognosis than sarcomatoid or biphasic disease. Histologic subtype also influences treatment selection — for example, current ASCO guidance on maximal surgical cytoreduction specifically emphasizes highly selected patients with favorable features, including epithelioid histology.

Imaging for Staging

The purpose of staging imaging is not simply to confirm that a pleural mass exists. Doctors need to evaluate total pleural tumor extent, fissural involvement, neighboring structures, regional lymph nodes, the opposite chest, and potential distant metastatic disease. Depending on the clinical situation, evaluation can include CT and additional imaging such as PET/CT or MRI. No individual imaging modality provides complete diagnostic accuracy, and findings that would substantially change treatment may sometimes require further evaluation or tissue confirmation.

Lymph-Node Assessment

Stage 1 requires N0 — no regional lymph-node involvement has been identified. Accurate nodal assessment is particularly important when aggressive local treatment or surgery is being considered. A tumor that remains T1 but is found to involve N1 regional lymph nodes would no longer be Stage 1 under Version 9; it would instead meet a Stage 2 grouping, T1 N1 M0. This illustrates why a patient should not be described as having Stage 1 disease based only on the appearance of the primary pleural tumor.

Clinical Stage vs Pathologic Stage

Pleural mesothelioma can have both a clinical and, when surgery is performed, a pathologic stage. Clinical staging is based on information available before definitive surgery, including imaging, biopsy, physical and clinical findings, and assessment of lymph nodes and distant disease; Version 9 clinical T staging uses quantitative CT measurements such as Psum and Fmax. If surgery is performed, tissue removed during the operation can provide additional information and produce a pathologic stage. Clinical and pathologic stages do not always match, since surgery can reveal disease that was not apparent on preoperative imaging.

Is Stage 1 Mesothelioma Resectable?

Many Stage 1 pleural mesotheliomas may appear anatomically resectable. However, Stage 1 does not automatically mean surgery should be performed. This distinction is crucial for appropriate treatment planning.

Resectability asks whether maximal removal of visible tumor can reasonably be achieved. Treatment suitability asks a broader question: would major surgery provide a favorable balance of potential benefit and risk for this particular patient?

Current ASCO guidance states that surgical cytoreduction should not be offered routinely to all patients based solely on anatomical resectability. Instead, it should be reserved for highly selected patients with favorable clinical characteristics after comprehensive staging and multidisciplinary review.

Surgery for Stage 1 Mesothelioma

Surgical cytoreduction may be considered for selected patients with early pleural mesothelioma. Factors supporting consideration of surgery can include early clinical T category, N0 disease, epithelioid histology, adequate cardiopulmonary reserve, good functional status, absence of significant contraindications, and the ability to undergo multimodality treatment.

ASCO’s current guidance particularly identifies clinical T1–T3 N0 epithelioid tumors as the favorable group in which maximal surgical cytoreduction may be considered. This makes a patient with Stage 1 T1 N0 disease anatomically relevant for surgical evaluation, but histology and overall fitness remain essential.

Pleurectomy/Decortication

Pleurectomy/decortication is a lung-sparing surgical approach intended to remove visible pleural tumor while preserving the underlying lung. The exact extent of surgery can vary depending on tumor involvement and institutional practice. Mesothelioma surgery is technically complex and should be evaluated at centers with specific experience in pleural mesothelioma.

Extrapleural Pneumonectomy

Extrapleural pneumonectomy is a more extensive procedure involving removal of the affected lung together with additional involved pleural and adjacent tissues. Because of its greater physiologic impact and potential morbidity, it is not an operation that should be presented as routine therapy for Stage 1 disease. Modern treatment selection increasingly emphasizes careful patient selection and lung-sparing approaches when maximal surgical cytoreduction is undertaken, and lung preservation is feasible.

When Surgery Is Used, It Is Usually Part of a Broader Strategy

Even when all visible tumor is removed, microscopic mesothelioma cells may remain. Therefore, surgery should not be regarded as a guarantee of complete disease eradication. Current ASCO guidance states that maximal surgical cytoreduction alone is generally insufficient and that additional antineoplastic therapy should be incorporated when appropriate. Treatment can therefore involve combinations or sequences of surgery, systemic therapy, and radiation therapy in selected situations. The specific combination and sequence of treatments may differ among patients and specialized mesothelioma centers. Our treatment guide covers these approaches across all stages.

Chemotherapy

Platinum-based chemotherapy with pemetrexed remains an established systemic treatment for pleural mesothelioma. The platinum component is commonly cisplatin or carboplatin.

In patients undergoing a surgery-based multimodality strategy, systemic chemotherapy can be given before or after surgery depending on the treatment plan. Current ASCO guidance allows pemetrexed/platinum chemotherapy to be incorporated into perioperative treatment for appropriately selected surgical patients.

Immunotherapy

Immunotherapy has significantly changed systemic treatment of pleural mesothelioma. For patients who require first-line systemic therapy, current treatment options can include immune-checkpoint blockade depending on histology, resectability, medical history, contraindications, and treatment goals.

Nivolumab Plus Ipilimumab — Nivolumab combined with ipilimumab is an established first-line systemic treatment option for newly diagnosed pleural mesothelioma and has an FDA indication for unresectable malignant pleural mesothelioma. The benefit of immunotherapy is particularly important in nonepithelioid disease, although treatment selection should be individualized.

Pembrolizumab Plus Platinum-Pemetrexed — For adults with unresectable advanced or metastatic malignant pleural mesothelioma, pembrolizumab combined with pemetrexed and platinum chemotherapy is an FDA-approved first-line treatment option. The FDA approved this combination in September 2024. For a patient with Stage 1 disease, systemic treatment decisions depend on the specific clinical situation rather than stage number alone.

Is Immunotherapy Used Before Surgery? This is an evolving area. Current ASCO guidance states that neoadjuvant immunotherapy-based treatment may be offered as an option in surgical candidates, though the strength of evidence is lower than for established systemic treatment in unresectable disease. This is different from saying that every Stage 1 surgical candidate should receive immunotherapy before surgery. An experienced multidisciplinary team should determine the appropriate sequencing of treatments.

Radiation Therapy

Radiation therapy can play a role in selected pleural mesothelioma treatment strategies, but its use is highly individualized. Potential roles can include selected multimodality treatment, local tumor control, treatment of specific sites, and palliation of pain or other symptoms. Radiation treatment of the pleura can be technically challenging because of the proximity of the lungs, heart, esophagus, spinal cord, and other structures, and should therefore be planned by a radiation oncology team experienced with thoracic malignancies when possible.

Multidisciplinary Treatment

A multidisciplinary team should ideally evaluate Stage 1 pleural mesothelioma. That team can include thoracic surgery, medical oncology, radiation oncology, pulmonology, thoracic radiology, thoracic pathology, palliative medicine, and specialized nursing and supportive-care professionals. The purpose of multidisciplinary review is not solely to recommend additional treatment — it is to identify the treatment strategy most appropriate for the individual patient.

Stage 1 Mesothelioma Prognosis

Stage is an important prognostic factor, and Stage 1 generally represents a more favorable anatomical situation than later-stage pleural mesothelioma. However, stage should not be used alone to predict a person’s outcome.

Other important factors include epithelioid versus biphasic or sarcomatoid histology, tumor biology, age, performance status, cardiopulmonary health, lymph-node status, whether surgery is appropriate, completeness of cytoreduction when performed, response to systemic therapy, laboratory findings, and other medical conditions. Consequently, individuals with the same Stage 1 classification may experience markedly different clinical courses. Our prognosis guide discusses these factors across all stages.

Stage 1 Mesothelioma Life Expectancy

There is no single medically reliable life-expectancy number that applies to every person with Stage 1 mesothelioma. Numbers reported online can be misleading because studies may involve different AJCC staging editions, definitions of Stage 1, treatment eras, surgical techniques, histologic subtypes, patient-selection criteria, institutions, and follow-up periods. A study based on an older Stage IA/IB system should not automatically be interpreted as describing AJCC Version 9 Stage I. Population-level statistics cannot predict individual patient outcomes.

SEER Survival Statistics Are Not AJCC Stage 1 Statistics

Another common source of confusion involves SEER survival data. SEER often groups cancer as localized, regional, or distant. These categories are useful for population-level statistics; however, SEER “localized” disease is not the same classification as AJCC Stage I. SEER categories should therefore not simply be relabeled as Stage 1, Stage 2, Stage 3, and Stage 4 survival statistics. This distinction is essential for the accurate presentation of prognostic information.

Can Stage 1 Mesothelioma Be Cured?

Stage 1 provides an opportunity to consider aggressive treatment in appropriately selected patients, but mesothelioma remains a difficult cancer to cure. The disease often grows diffusely along pleural surfaces, and microscopic tumor can remain even after extensive surgery. For this reason, treatment is generally discussed in terms of maximal disease control, prolonging survival when possible, delaying recurrence or progression, preserving function, controlling symptoms, and maintaining quality of life. Some carefully selected patients may achieve prolonged disease control following multimodality treatment; however, no treatment should be described as guaranteeing a cure.

Can Stage 1 Mesothelioma Come Back?

Yes. Recurrence can occur even after apparently complete macroscopic tumor removal. Possible recurrence patterns can include local or regional disease and, over time, distant progression. This underscores the importance of ongoing follow-up after treatment. The treating team determines surveillance based on the treatment received, clinical status, imaging findings, and institutional protocol.

Is Stage 1 Mesothelioma Terminal?

A Stage 1 diagnosis should not automatically be described as “terminal.” It is a serious cancer diagnosis, but Stage 1 represents nonmetastatic disease without identified regional lymph-node involvement under the current staging system. Some patients are eligible for active multimodality treatment. Therapeutic goals and expected prognosis should be discussed on an individual basis rather than inferred solely from the diagnosis of “mesothelioma.”

Why a Mesothelioma Specialist Matters

Pleural mesothelioma is rare. Diagnosis, staging, pathology interpretation, and treatment selection can therefore benefit from experience with this specific disease.

A specialist evaluation can be particularly useful when deciding whether Stage 1 has been assigned accurately, whether pathology should be reviewed, whether lymph-node staging is sufficient, whether surgery is appropriate, which surgical approach should be considered, whether systemic therapy should be given before or after surgery, and whether a clinical trial is appropriate.

Seeking another opinion does not necessarily mean the original treatment recommendation was wrong. For rare cancers, obtaining a specialist opinion can provide additional assurance before making major treatment decisions. Our find a specialist guide can help with that search.

Clinical Trials for Stage 1 Mesothelioma

Clinical trials are not limited to Stage 4 disease. Studies in earlier-stage pleural mesothelioma may investigate perioperative systemic therapy, immunotherapy before surgery, new combinations of systemic treatments, biomarkers, improved surgical strategies, radiation techniques, and methods of predicting recurrence.

Eligibility depends on the specific trial protocol. Patients interested in clinical trials are encouraged to consult with a mesothelioma treatment team prior to initiating therapy, when feasible.

What to Do After a Stage 1 Diagnosis

A Stage 1 diagnosis can involve complex decisions despite being the earliest formal stage. Useful questions for the treating team include:

1. Is my diagnosis definitely diffuse pleural mesothelioma?
2. Is my stage based on AJCC Version 9?
3. What are my exact T, N, and M categories?
4. What are my Psum and Fmax measurements?
5. Has my pathology been reviewed by a pathologist experienced in mesothelioma?
6. What is my histologic subtype?
7. Has regional lymph-node involvement been adequately assessed?
8. Is my disease considered technically resectable?
9. Am I an appropriate candidate for surgical cytoreduction?
10. Which surgical approach would be considered and why?
11. What are the expected benefits and risks of surgery in my specific case?
12. Should systemic treatment be given before or after surgery?
13. Are there reasons to choose chemotherapy, immunotherapy, or another strategy?
14. Should I obtain a second opinion at a high-volume mesothelioma center?
15. Are there clinical trials for which I may qualify?
16. What is the goal of treatment in my case?
17. How will treatment affect breathing, function, and quality of life?
18. What follow-up will be needed after treatment?

Frequently Asked Questions

What is Stage 1 mesothelioma?

Stage 1 pleural mesothelioma is the earliest stage in the current AJCC Version 9 system. It is defined as T1 N0 M0: the tumor meets T1 criteria, no regional lymph-node spread has been identified, and there is no distant metastasis.

Is Stage 1 mesothelioma divided into Stage 1A and Stage 1B?

Not under the current AJCC Version 9 system. Stage IA and IB terminology may appear in information based on older staging editions. Current Stage I is T1 N0 M0.

What does T1 mean in Stage 1 mesothelioma?

For clinical staging, T1 means the tumor is limited to the ipsilateral pleura, with Psum ≤12 mm and no qualifying fissural involvement, Fmax ≤5 mm.

Has Stage 1 mesothelioma spread to lymph nodes?

No regional lymph-node involvement is identified in Stage 1. Its nodal category is N0.

Has Stage 1 mesothelioma metastasized?

No. Stage 1 is M0, meaning distant metastasis has not been identified.

Can Stage 1 mesothelioma be surgically removed?

Some patients with Stage 1 disease may be candidates for surgical cytoreduction, but Stage 1 alone does not establish that surgery is appropriate. Histology, cardiopulmonary fitness, tumor anatomy, overall health, and multidisciplinary assessment are important.

Is surgery automatically recommended for Stage 1 mesothelioma?

No. Current ASCO guidance states that surgical cytoreduction should not be offered routinely based only on anatomical resectability. It is intended for highly selected patients with favorable characteristics after comprehensive staging.

Which histology is most favorable for surgery?

Current ASCO guidance particularly identifies epithelioid tumors with clinical T1–T3 N0 disease among favorable characteristics for consideration of maximal surgical cytoreduction.

Can sarcomatoid Stage 1 mesothelioma be treated with surgery?

Histology substantially affects treatment planning. Current ASCO guidance recommends against maximal surgical cytoreduction for histologically confirmed sarcomatoid mesothelioma.

Does Stage 1 mesothelioma require chemotherapy?

Not every patient follows the same treatment sequence. Systemic therapy can be incorporated into multimodality treatment depending on surgical candidacy, histology, treatment strategy, comorbidities, and patient preferences.

Can immunotherapy be used for mesothelioma?

Yes. Immunotherapy is an established component of modern pleural mesothelioma treatment. Its role in an individual Stage 1 patient depends on whether systemic treatment is indicated and on the overall treatment strategy.

Is Stage 1 mesothelioma curable?

Stage 1 provides greater opportunity for aggressive treatment than more advanced disease, but mesothelioma remains difficult to cure and recurrence can occur even after extensive treatment. Treatment goals should be discussed individually.

What is the survival rate for Stage 1 mesothelioma?

There is no single Version 9 Stage 1 survival percentage that accurately predicts an individual’s outcome. Many published studies use older staging editions or different patient populations, and SEER localized survival statistics are not equivalent to AJCC Stage I.

Should I get a second opinion?

A second opinion can be particularly useful in a rare cancer such as mesothelioma, especially before major surgery or when there is uncertainty about pathology, staging, resectability, or treatment sequencing.

Medical References

1. American Joint Committee on Cancer. Diffuse Pleural Mesothelioma. AJCC Cancer Staging System, Version 9. American College of Surgeons; 2024.
2. American Cancer Society. Stages of Mesothelioma. Last revised February 3, 2026.
3. International Association for the Study of Lung Cancer. Pleural Mesothelioma TNM Definitions — 9th Edition.
4. Kindler HL, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43:1006–1038. doi:10.1200/JCO-24-02425.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 2.2026.
6. National Cancer Institute. Mesothelioma Treatment. Updated May 16, 2025.
7. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. September 17, 2024.
8. U.S. Food and Drug Administration. Nivolumab plus ipilimumab prescribing information for unresectable malignant pleural mesothelioma.

Editorial and Medical Review Information